U.S. pharma raises alarm over Trump’s proposed measures against Chinese drugs; China clarifies the type of employees to be bound by non-compete clauses; and Some stablecoin issuers complain that Hong Kong’s regime is too stringent.
Part I of this series explained China’s general rules on foreign-related jurisdiction. In Part II, Jianwei(Jerry) Fang, Ke Dong and Haoyi Sun of Zhong LunLaw Firm show how Chinese courts will, in practice, assert jurisdiction in civil, administrative or criminal contexts involving foreign elements, and describe a new “blocking statute” that reflects China’s response to foreign long-arm claims.
Hainan launches pilot program expanding financial products access to foreigners; Chinese companies reconsider pivot to Southeast Asia as region targeted by U.S. tariffs; and Chinese regulator puts U.S. outbound investments on hold.
Wei Huang, managing partner, and Kexin Chen, associate, at Beijing Tian Yuan Law Firm provide a comprehensive interpretation of a core provision of China’s revised Anti-Unfair Competition Law and its impact on enterprises of all sizes
FRAND ruling undercuts London’s global ambitions as Samsung’s U.K. win against ZTE risks backfiring in Germany; U.S. consultancy giant asks staff to pause generative AI-related consultancy work in China; and U.S. toymakers diversify away from China amid tariff challenges
China rolls out tax breaks for foreign investors reinvesting profits locally; China remains key private equity market but firms are starting to diversify investments; U.S. Congressional bill that targets Chinese AI tools like Deepseek has bipartisan support
Chinese manufacturers increase exports to non-U.S. markets; Revisions to the Anti-Unfair Competition Law address challenges to fair competition; China's data centers in Tibet aim to power much of China's AI
U.S. to tighten disclosure obligations of foreign listed companies, targeting China; China to allow local investors to invest more in overseas assets under QDII; and EU issues measures to restrict Chinese medical device manufacturers from accessing public procurement contracts
Western companies concerned about China's demand for sensitive rare earths information; Irish data regulators target transparency and transfer impact assessment failures in landmark decision; and China's largest insurer plans to raise HK$11.77 billion through convertible bond listing in Frankfurt
Xiangxiang Ma, a partner of Anjie Broad Law Firm, explores the various ways in which a recent U.S. executive order on drug pricing is impacting Chinese pharmaceutical companies’ license-out model
